EP1558341A4 - Transkriptionsfaktor modulierendeverbindungen und ihre verwendung - Google Patents
Transkriptionsfaktor modulierendeverbindungen und ihre verwendungInfo
- Publication number
- EP1558341A4 EP1558341A4 EP03783155A EP03783155A EP1558341A4 EP 1558341 A4 EP1558341 A4 EP 1558341A4 EP 03783155 A EP03783155 A EP 03783155A EP 03783155 A EP03783155 A EP 03783155A EP 1558341 A4 EP1558341 A4 EP 1558341A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- transcription factor
- modulating compounds
- factor modulating
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Eyeglasses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42331902P | 2002-11-01 | 2002-11-01 | |
US423319P | 2002-11-01 | ||
US42591602P | 2002-11-13 | 2002-11-13 | |
US425916P | 2002-11-13 | ||
PCT/US2003/035205 WO2004041209A2 (en) | 2002-11-01 | 2003-11-03 | Transcription factor modulating compounds and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1558341A2 EP1558341A2 (de) | 2005-08-03 |
EP1558341A4 true EP1558341A4 (de) | 2010-09-08 |
Family
ID=32314482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03783155A Withdrawn EP1558341A4 (de) | 2002-11-01 | 2003-11-03 | Transkriptionsfaktor modulierendeverbindungen und ihre verwendung |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1558341A4 (de) |
JP (3) | JP2006513162A (de) |
AU (1) | AU2003291226B2 (de) |
CA (1) | CA2504448C (de) |
WO (1) | WO2004041209A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1462105A1 (de) * | 2003-03-28 | 2004-09-29 | Procorde GmbH | Aktivierungs-spezifische Inhibitoren von NF-kB und Methode zur Behandlung entzündlicher Prozesse be kardiovaskulären Erkrankungen |
US7132440B2 (en) | 2003-04-17 | 2006-11-07 | Janssen Pharmaceutica, N.V. | Substituted benzimidazoles and imidazo-[4,5]-pyridines |
CA2562763A1 (en) * | 2004-04-23 | 2006-07-20 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
WO2007016292A2 (en) * | 2005-07-27 | 2007-02-08 | Vertex Pharmaceuticals Incorporated | Heterocyclic amides as biofilm modulators |
JP5390186B2 (ja) * | 2005-08-12 | 2014-01-15 | ユナイテッド ステイツ ガバメント アズ レプリゼンティッド バイ ザ セクレタリー オブ ザ ユナイテッド ステイツ アーミー アンド ザ ユーエス アーミー メディカル リサーチ アンド マティリ | 広い抗菌スペクトルを有する抗菌性化合物 |
US20070178054A1 (en) * | 2005-11-09 | 2007-08-02 | Madhyastha Srinivasa | Oral antimicrobial composition |
AU2007351886A1 (en) * | 2006-06-23 | 2008-10-30 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
BRPI0719761A2 (pt) | 2006-12-01 | 2014-01-21 | Laclede Inc | Uso de enzimas hidrolíticas e oxidativas para dissolver biofilme nas orelhas |
CA2681813A1 (en) * | 2007-03-27 | 2009-01-08 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
EP2000140A1 (de) | 2007-06-05 | 2008-12-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Verwendung 3-Oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidinen oder 3-Oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidinen zur Herstellung pharmazeutischer Zubereitungen zur Behandlung von Krebs |
WO2010027762A1 (en) * | 2008-09-04 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Indolizine inhibitors of leukotriene production |
GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
US20110059962A1 (en) * | 2009-04-22 | 2011-03-10 | Alekshun Michael N | Transcription factor modulating compounds and methods of use thereof |
ES2568455T3 (es) | 2010-06-01 | 2016-04-29 | Summit Therapeutics Plc | Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile |
WO2011151617A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
WO2011151619A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
WO2011151620A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
WO2011151618A2 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile-associated disease |
US9382226B2 (en) * | 2010-07-21 | 2016-07-05 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
US9332757B2 (en) | 2010-10-25 | 2016-05-10 | Vanderbilt University | Composition for inhibition of insect host sensing |
US9677978B2 (en) * | 2011-05-02 | 2017-06-13 | José Carlos Lapenna | Fixative solution, for fixation and preservation of biological samples |
EP3653054A1 (de) | 2011-05-06 | 2020-05-20 | Vanderbilt University | Zusammensetzungen zur hemmung einer insektenwirtserfassung |
US9079935B2 (en) | 2012-08-13 | 2015-07-14 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Reducing risk of contracting Clostridium-difficile associated disease |
ITMI20132192A1 (it) * | 2013-12-23 | 2015-06-24 | Purisa S R L | Composti antimicrobici |
WO2016127102A2 (en) | 2015-02-06 | 2016-08-11 | Ernesto Abel-Santos | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis |
EP3273779A4 (de) | 2015-03-25 | 2018-09-05 | Vanderbilt University | Binäre zusammensetzungen als disruptoren von orco-vermittelter geruchsstoffwahrnehmung |
US10472687B2 (en) | 2016-01-08 | 2019-11-12 | Institute For Systems Biology | Methods to identify antituberculosis compounds |
BR112020003676A2 (pt) | 2017-09-15 | 2020-09-01 | Aduro Biotech, Inc. | compostos de pirazolopirimidinona e usos dos mesmos |
KR20220024617A (ko) | 2019-07-17 | 2022-03-03 | 서밋 (옥스포드) 리미티드 | 리디닐라졸 및 이의 결정 형태의 제조방법 |
JP7458622B2 (ja) | 2019-09-18 | 2024-04-01 | 学校法人東京農業大学 | 抗生物質耐性微生物の耐性を低下させる物質及び抗生物質耐性微生物の耐性を低下させる方法 |
CN110840897B (zh) * | 2019-11-28 | 2023-08-08 | 河北旺发生物科技有限公司 | 金属β-内酰胺酶抑制剂 |
CN111166743B (zh) * | 2020-01-02 | 2022-03-22 | 中国医学科学院医药生物技术研究所 | 一类含噻唑结构化合物的抗感染用途 |
GB202100471D0 (en) | 2021-01-14 | 2021-03-03 | Summit Oxford Ltd | Preparation of antibacterial compounds |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE674202A (de) * | 1964-12-31 | 1966-06-22 | ||
US3325356A (en) * | 1965-08-20 | 1967-06-13 | Merck & Co Inc | Compositions and method for treating helminthiasis |
DE1545718A1 (de) * | 1964-12-07 | 1969-07-10 | Ciba Geigy | Benzimidazole |
US3516999A (en) * | 1966-03-26 | 1970-06-23 | Shionogi Seiyaku Kk | Benzimidazole derivatives |
FR2047462A5 (en) * | 1969-05-08 | 1971-03-12 | Hoechst Ag | 1-hydroxy-benzimidazole-z-carbpxy acid - amides and esters |
DE2109331A1 (de) * | 1970-02-27 | 1971-09-02 | Merck & Co Ine , Rahway, N J (V St A) | 1 Oxybenzimidazole |
US3743738A (en) * | 1970-03-05 | 1973-07-03 | Merck & Co Inc | Substituted benzimidazoles as anthelmintic agents |
CH554892A (de) * | 1970-03-05 | 1974-10-15 | Merck & Co Inc | Verfahren zur herstellung von 1,5-substituierten oder 1,6substituierten benzimidazolen. |
CH556868A (de) * | 1970-03-05 | 1974-12-13 | Merck & Co Inc | Verfahren zur herstellung von 1-hydroxy-5-(oder 6-)-carbonyl-amino-2-(4'-thiazolyl)-benzimidazolen. |
WO2004001058A2 (en) * | 2001-05-04 | 2003-12-31 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
CA2002859C (en) * | 1988-11-29 | 1998-12-29 | Jean P. F. Van Wauwe | Method of treating epithelial disorders |
WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
CA2341409A1 (en) * | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
-
2003
- 2003-11-03 CA CA2504448A patent/CA2504448C/en not_active Expired - Fee Related
- 2003-11-03 JP JP2004550495A patent/JP2006513162A/ja active Pending
- 2003-11-03 EP EP03783155A patent/EP1558341A4/de not_active Withdrawn
- 2003-11-03 AU AU2003291226A patent/AU2003291226B2/en not_active Ceased
- 2003-11-03 WO PCT/US2003/035205 patent/WO2004041209A2/en active Application Filing
-
2010
- 2010-05-11 JP JP2010109145A patent/JP5175316B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-27 JP JP2012039805A patent/JP2012131813A/ja active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1545718A1 (de) * | 1964-12-07 | 1969-07-10 | Ciba Geigy | Benzimidazole |
BE674202A (de) * | 1964-12-31 | 1966-06-22 | ||
US3325356A (en) * | 1965-08-20 | 1967-06-13 | Merck & Co Inc | Compositions and method for treating helminthiasis |
US3516999A (en) * | 1966-03-26 | 1970-06-23 | Shionogi Seiyaku Kk | Benzimidazole derivatives |
FR2047462A5 (en) * | 1969-05-08 | 1971-03-12 | Hoechst Ag | 1-hydroxy-benzimidazole-z-carbpxy acid - amides and esters |
DE2109331A1 (de) * | 1970-02-27 | 1971-09-02 | Merck & Co Ine , Rahway, N J (V St A) | 1 Oxybenzimidazole |
US3743738A (en) * | 1970-03-05 | 1973-07-03 | Merck & Co Inc | Substituted benzimidazoles as anthelmintic agents |
CH554892A (de) * | 1970-03-05 | 1974-10-15 | Merck & Co Inc | Verfahren zur herstellung von 1,5-substituierten oder 1,6substituierten benzimidazolen. |
CH556868A (de) * | 1970-03-05 | 1974-12-13 | Merck & Co Inc | Verfahren zur herstellung von 1-hydroxy-5-(oder 6-)-carbonyl-amino-2-(4'-thiazolyl)-benzimidazolen. |
WO2004001058A2 (en) * | 2001-05-04 | 2003-12-31 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
Non-Patent Citations (2)
Title |
---|
DE STEVENS G ET AL: "Derivatives of 1-Hydroxybenzimidazoles and 1-Hydroxyindoles and Their Central Depressant Effects", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/JM00314A018, vol. 10, no. 2, 1 March 1967 (1967-03-01), pages 211 - 214, XP002980391, ISSN: 0022-2623 * |
MINISCI, F. ET AL.: "Addition reaction of nitrile oxides to aromatic nitroso derivatives. A novel synthesis of the benzimidazole ring", TETRAHEDRON LETTERS, no. 12, 1963, pages 785 - 790, XP002594210, ISSN: 0040-4039 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010235612A (ja) | 2010-10-21 |
AU2003291226A1 (en) | 2004-06-07 |
EP1558341A2 (de) | 2005-08-03 |
AU2003291226B2 (en) | 2009-06-04 |
CA2504448A1 (en) | 2004-05-21 |
JP2012131813A (ja) | 2012-07-12 |
JP2006513162A (ja) | 2006-04-20 |
JP5175316B2 (ja) | 2013-04-03 |
WO2004041209A3 (en) | 2004-09-30 |
WO2004041209A2 (en) | 2004-05-21 |
CA2504448C (en) | 2012-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1558341A4 (de) | Transkriptionsfaktor modulierendeverbindungen und ihre verwendung | |
EP1524974A4 (de) | Transkriptionsfaktor modulierende verbindungen und verfahren zur verwendung davon | |
IL210693A0 (en) | Transcription factor modulating compounds and methods of use thereof | |
AU2003217870A8 (en) | Pini-modulating compounds and methods of use thereof | |
AU2003225669A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003225668A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003295801A8 (en) | Modulation of hif1alpha and hif2alpha expression | |
AU2003303128A1 (en) | Inhibitors and methods of use thereof | |
EP1465615A4 (de) | Trizyklische bisenon-derivate und verfahren zu ihrer verwendung | |
AU2003275311A1 (en) | Solid micro-perforators and methods of use | |
EP1521747A4 (de) | Modulatoren von rezeptor-typ-kinase und anwendungsverfahren | |
HK1079789A1 (zh) | 血管靜態毒性試劑及其使用方法 | |
AU2003259717A8 (en) | Modulators of rabggt and methods of use thereof | |
AU2003288902A1 (en) | Microcapsules and methods of use | |
EP1567515A4 (de) | Neue lapachonverbindungen und verfahren zu deren anwendung | |
EP1476150A4 (de) | Carboxyfullerene und verwendungsverfahren dafür | |
AU2003275056A1 (en) | Novel lapacho compounds and methods of use thereof | |
EP1633749A4 (de) | Deazaflavinverbindungen und verfahren zu deren anwendung | |
AU2002337913A1 (en) | Glycosulfopeptide inhibitors and methods of use thereof | |
AU2003265394A1 (en) | Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use | |
AU2003252026A1 (en) | Npc1l1 (npc3) and methods of use thereof | |
EP1545287A4 (de) | Vasoregulierende verbindungen und anwendungsverfahren | |
AU2003287802A1 (en) | Palpometer and methods of use thereof | |
AU2003216354A8 (en) | Modulators of paraptosis and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050527 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100809 |
|
17Q | First examination report despatched |
Effective date: 20110222 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130601 |